Trump’s pharma holdings surged from $1.7 million in 2024 to $56.2 million as drugmakers gained Medicare exemptions, Democrats say

A report by congressional Democrats says President Trump's pharmaceutical holdings rose from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025, including up to $39.1 million in companies benefiting from exemptions to Medicare drug-price negotiations. The report says his portfolio bought up to $2.55 million in shares of those companies on three dates before he signed the law; the White House says the portfolio is independently managed and denies any conflict of interest. The report estimates beneficiaries of Keytruda and Opdivo could pay roughly $5,000 more annually without Medicare-negotiated prices.

Analysis

The investable issue is not the portfolio allegation itself, but whether the expanded orphan-drug carveout measurably delays Medicare price pressure on specific products. The report’s estimates are partisan analysis, and the article does not establish that Keytruda or Opdivo qualify for the exemption or quantify any change to their realized pricing. Verify eligibility, negotiation timing, and exposure by indication before translating the claims into earnings revisions for MRK or BMY. ABBV’s reported holding is not evidence that its business benefits from the carveout.

Near term, the principal risk is headline-driven scrutiny and policy uncertainty, not a demonstrated change in cash flows. Over 1–3 months, watch for independent analysis, CMS implementation details, and any legislative or oversight response. Over 6–18 months, the carveout could support pricing durability for qualifying products, while political backlash may increase the odds of narrowing or repeal; patent life, pipeline replacement, and actual Medicare sales remain more consequential company-specific drivers. The contrarian point: markets may overreact to the conflict narrative while underweighting the possibility that a policy framed as affordability relief still preserves pricing for selected drugs. Conversely, do not capitalize presumed savings until eligibility and timing are confirmed.

Key Decisions for Investors

• No standalone directional trade in ABBV, BMY, or MRK on this report. Treat the investment disclosures as a governance and headline-risk signal, not proof of a near-term earnings catalyst.
• Set an alert for CMS eligibility and timing details for Keytruda and Opdivo. If confirmed to benefit, reassess MRK/BMY estimates against Medicare exposure and negotiation timing before considering a relative-value position.
• For existing concentrated exposure to MRK or BMY, review event-risk limits around policy announcements; a reversal or narrowing of the carveout is the key downside catalyst. Falsify the pricing-support thesis if final rules leave the relevant products eligible for negotiation on the expected schedule.
• Track independent confirmation of the reported holdings and any formal ethics or legislative action. Without that, avoid pricing a durable governance discount into ABBV, BMY, or MRK.